CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2022—Co-Diagnostics has entered into definitive agreements with Idaho Molecular and Advanced Conceptions in which both companies will become wholly owned subsidiaries of Co-Dx. Salt Lake City–based Co-Dx has been working with Idaho Molecular and Advanced Conceptions on the development of Co-Dx’s at-home, point-of-care diagnostic device. The transactions will provide Co-Dx with existing and future assets and intellectual property related to the platform.
Co-Dx said in a press statement that it expects the acquisition will streamline the commercialization of the Eikon platform and YourTest PCR device. The YourTest PCR device has been designed with specialized optics to accommodate multiplexed assays. The single-use YourTest PCR COVID-19 test cartridges are being designed to work with saliva or nasal swab samples. Samples would be analyzed in the reusable device and results would be displayed on users’ smartphones.